This important study reveals distinct representations of task-related information in the dendrites and somata of cortical neurons during sensorimotor learning and behavioral adaptation. The evidence ...

Governments put up railings and barriers and regulate supplies of certain drugs to prevent people from dying by suicide. But ...

When debates about animal minds, conscious machines, and even fetal awareness spill into public life, the science behind ...

A new analysis of approximately 600,000 research papers reveals structural limits to single-country security oversight of dual-use research and identifies trade-offs that policymakers face when ...

Authors make the case that empathy, individualized attention, and the ability to read a room are essential workplace skills.

Investing.com - Citizens maintains its market outperform rating on Uber Technologies (NYSE:UBER) with a $100 price target following the firm’s attendance at NVIDIA’s GTC event in San Jose, California ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Why the latest price target shift for NOTE matters to you ...

Deutsche Bank Chief Executive Christian Sewing disavowed an analyst's suggestion that Europe could dump Treasurys over the U.S. stance on Greenland, according to Treasury Secretary Scott Bessent. In a ...

NOTE stock remains under close watch as analysts maintain their Fair Value estimate at 206 SEK, even as the sector sees shifting valuation trends. While revenue growth projections and net profit ...

With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now. Highlighting the ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...